HLA-DQB1 expression on tumor cells is a novel favorable prognostic factor for relapse in early-stage lung adenocarcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(4):504–535.28404761
   PubMed Web of Science ®Google Scholar
• Group, N.M.A.C. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561–1571. doi:10.1016/S0140-6736(13)62159-524576776
   PubMed Web of Science ®Google Scholar
• Gold KA, Kim ES, Liu DD, et al. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014;20(7):1946–1954. doi:10.1158/1078-0432.CCR-13-195924366692
   PubMed Web of Science ®Google Scholar
• Wistuba II, Behrens C, Lombardi F, et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res. 2013;19(22):6261–6271. doi:10.1158/1078-0432.CCR-13-059624048333
   PubMed Web of Science ®Google Scholar
• Lu Y, Govindan R, Wang L, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis. 2012;33(5):1046–1054. doi:10.1093/carcin/bgs10022331473
   PubMed Web of Science ®Google Scholar
• Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358(11):1118–1128. doi:10.1056/NEJMoa070655018337602
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–99. doi:10.3322/caac.2138828094848
   PubMed Web of Science ®Google Scholar
• Li Z, Qing Y, Guan W, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol. 2014;74(4):777–786. doi:10.1007/s00280-014-2562-125107571
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-071315534099
   PubMed Web of Science ®Google Scholar
• Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355.
   PubMed Web of Science ®Google Scholar
• National Lung Screening Trial Research Team; Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–1991. doi:10.1056/NEJMoa120912023697514
   PubMed Web of Science ®Google Scholar
• van der Aalst CM, Ten Haaf K, de Koning HJ. Lung cancer screening: latest developments and unanswered questions. Lancet Respir Med. 2016;4(9):749–761. doi:10.1016/S2213-2600(16)30200-427599248
   PubMed Web of Science ®Google Scholar
• West H. Individualizing adjuvant therapy for early stage non-small cell lung cancer: we see the destination, but we don’t yet know the route. J Thorac Dis. 2015;7(3):235–237. doi:10.3978/j.issn.2072-1439.2015.01.0825922698
   PubMed Web of Science ®Google Scholar
• Pakkala S, Ramalingam SS. Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives. Curr Opin Oncol. 2016;28(2):150–158. doi:10.1097/CCO.000000000000026926809014
   PubMed Web of Science ®Google Scholar
• Lee ES, Son DS, Kim SH, et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res. 2008;14(22):7397–7404. doi:10.1158/1078-0432.CCR-07-493719010856
   PubMed Web of Science ®Google Scholar
• Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356(1):11–20. doi:10.1056/NEJMoa06009617202451
   PubMed Web of Science ®Google Scholar
• Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006;66(15):7466–7472. doi:10.1158/0008-5472.CAN-06-119116885343
   PubMed Web of Science ®Google Scholar
• Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 2006;3(12):e467. doi:10.1371/journal.pmed.003046717194181
   PubMed Web of Science ®Google Scholar
• Okayama H, Schetter AJ, Ishigame T, et al. The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2884–2894. doi:10.1158/1055-9965.EPI-14-018225242053
   PubMed Web of Science ®Google Scholar
• Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8(8):816–824. doi:10.1038/nm73312118244
   PubMed Web of Science ®Google Scholar
• Robles AI, Arai E, Mathe EA, et al. An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers. J Thorac Oncol. 2015;10(7):1037–1048. doi:10.1097/JTO.000000000000056026134223
   PubMed Web of Science ®Google Scholar
• Wank R, Meulen JT, Luande J, Eberhardt HC, Pawlita M. Cervical intraepithelial neoplasia, cervical carcinoma, and risk for patients with HLA-DQB1*0602,*301,*0303 alleles. Lancet. 1993;341(8854):1215. doi:10.1016/0140-6736(93)91043-L
   PubMed Web of Science ®Google Scholar
• David AL, Taylor GM, Gokhale D, et al. HLA-DQB1*03 and cervical intraepithelial neoplasia type III. Lancet. 1992;340(8810):52. doi:10.1016/0140-6736(92)92464-Q
   PubMed Web of Science ®Google Scholar
• He Y, Rozeboom L, Rivard CJ, et al. MHC class II expression in lung cancer. Lung Cancer. 2017;112:75–80. doi:10.1016/j.lungcan.2017.07.03029191604
   PubMed Web of Science ®Google Scholar
• Londei M, Lamb JR, Bottazzo GF, Feldmann M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature. 1984;312(5995):639–641.6334239
   PubMed Web of Science ®Google Scholar
• Herkel J, Jagemann B, Wiegard C, et al. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes. Hepatology. 2003;37(5):1079–1085. doi:10.1053/jhep.2003.5019112717388
   PubMed Web of Science ®Google Scholar
• Sconocchia G, Eppenberger-Castori S, Zlobec I, et al. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia. 2014;16(1):31–42.24563618
   PubMed Web of Science ®Google Scholar
• Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund L-T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14(16):5220–5227. doi:10.1158/1078-0432.CCR-08-013318698040
   PubMed Web of Science ®Google Scholar
• Brambilla E, Le Teuff G, Marguet S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol. 2016;34(11):1223–1230. doi:10.1200/JCO.2015.63.097026834066
   PubMed Web of Science ®Google Scholar